(PharmaNewsWire.Com, July 01, 2017 ) Albany, New York, June 30, 2017: Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Usher Syndrome Pipeline Review, H1 2017” to its report offerings. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Usher Syndrome - Pipeline Review, H1 2017, provides an overview of the Usher Syndrome (Genetic Disorders) pipeline landscape.
Usher syndrome is an inherited condition characterized by hearing impairment and progressive vision loss. The major symptoms of Usher syndrome are hearing loss and an eye disorder called retinitis pigmentosa. Risk factors include retinal degeneration, prolonged, unprotected exposure to sunlight may accelerate vision loss. Treatment includes cochlear implants, hearing aids and Vitamin A supplementation.
Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Usher Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Usher Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Usher Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Usher Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Discovery stages are 2 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Usher Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Usher Syndrome (Genetic Disorders). - The pipeline guide reviews pipeline therapeutics for Usher Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Usher Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Usher Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Usher Syndrome (Genetic Disorders)
Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Usher Syndrome (Genetic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Usher Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Usher Syndrome - Overview Usher Syndrome - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Usher Syndrome - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Usher Syndrome - Companies Involved in Therapeutics Development Amgen Inc Editas Medicine Inc ProQR Therapeutics NV Sanofi Usher Syndrome - Drug Profiles Gene Therapy for Usher Syndrome - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy to Activate MYO7A for Usher Syndrome - Drug Profile Product Description Mechanism Of Action R&D Progress NT-501 - Drug Profile Product Description Mechanism Of Action R&D Progress QRX-411 - Drug Profile Product Description Mechanism Of Action R&D Progress QRX-421 - Drug Profile Product Description Mechanism Of Action R&D Progress SAR-421869 - Drug Profile Product Description Mechanism Of Action R&D Progress
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of Pharmaceutical Market Research Reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
